Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants cleared or almost cleared in the short… compared with PUVA therapy (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with PUVA therapy (very low certainty).
1 finding from 1 review
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in wound size · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost of the intervention · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.4 [0.28, 0.57]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.27 [0.21, 0.34]
925 participants
High
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 6.78 [4.84, 9.49]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.49 [0.39, 0.61]
957 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 1.27 [0.48, 3.33]
408 participants
Low